Article

Ellis, RD, Mullen, GE, Pierce, M, Martin, LB, Miura, K, Fay, MP et al.. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27: 4104-4109

Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, MD 20852, USA.
Vaccine (Impact Factor: 3.49). 06/2009; 27(31):4104-9. DOI: 10.1016/j.vaccine.2009.04.077
Source: PubMed

ABSTRACT A Phase 1 study was conducted in 24 malaria naïve adults to assess the safety and immunogenicity of the recombinant protein vaccine apical membrane antigen 1-Combination 1 (AMA1-C1)/Alhydrogel with CPG 7909 in two different formulations (phosphate buffer and saline), and given at two different dosing schedules, 0 and 1 month or 0 and 2 months. Both formulations were well tolerated and frequency of local reactions and solicited adverse events was similar among the groups. Peak antibody levels in the groups receiving CPG 7909 in saline were not significantly different than those receiving CPG 7909 in phosphate. Peak antibody levels in the groups vaccinated at a 0,2 month interval were 2.52-fold higher than those vaccinated at a 0,1 month interval (p=0.037, 95% CI 1.03, 4.28). In vitro growth inhibition followed the antibody level: median inhibition was 51% (0,1 month interval) versus 85% (0,2 month interval) in antibody from samples taken 2 weeks post-second vaccination (p=0.056).

Download full-text

Full-text

Available from: Greg Mullen, Aug 25, 2015
0 Followers
 · 
178 Views
  • Source
    • "The combination of Al(OH) 3 and a CpG oligodeoxynucleotide (CpG) that activates via TLR9 can enhance antibody titers 10-fold or more over either adjuvant alone in mice [14]. In humans, CpG combined with Al(OH) 3 enhanced antibody titers against four different antigens by at least 5-fold compared to Al(OH) 3 as sole adjuvant,[15] [16] [17] [18] and, in one study where it was evaluated, also significantly enhanced antibody affinity[19]. Herein, we describe our findings in mice and monkeys testing the ability of CpG to enhance anti-nicotine antibody functionality induced in response to a model anti-nicotine vaccine comprised of trans-3′ aminomethylnicotine conjugated to diphtheria toxoid (3′AmNic-DT) as antigen and Al(OH) 3 as adjuvant. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tobacco smoking is one of the most preventable causes of morbidity and mortality, but current smoking cessation treatments have relatively poor long term efficacy. Anti-nicotine vaccines offer a novel mechanism of action whereby anti-nicotine antibodies (Ab) in circulation prevent nicotine from entering the brain, thus avoiding the reward mechanisms that underpin nicotine addiction. Since antibody responses are typically long lasting, such vaccines could potentially lead to better long-term smoking cessation outcomes. Clinical trials of anti-nicotine vaccines to date have not succeeded, although there was evidence that very high anti-nicotine Ab titers could lead to improved smoking cessation outcomes, suggesting that achieving higher titers in more subjects might result in better efficacy overall. In this study, we evaluated CpG (TLR9 agonist) and aluminum hydroxide (Al(OH)3) adjuvants with a model anti-nicotine antigen comprising trans-3'aminomethylnicotine (3'AmNic) conjugated to diphtheria toxoid (DT). Anti-nicotine Ab titers were significantly higher in both mice and non-human primates (NHP) when 3'AmNic-DT was administered with CpG/Al(OH)3 than with Al(OH)3 alone, and affinity was enhanced in mice. CpG also improved functional responses, as measured by nicotine brain levels in mice after intravenous administration of radiolabeled nicotine (30% versus 3% without CpG), or by nicotine binding capacity of NHP antisera (15-fold higher with CpG). Further improvement should focus on maximizing Ab function, which takes into account both titer and avidity, and this may require improved conjugate design in addition to adjuvants.
    International immunopharmacology 04/2013; 16(1). DOI:10.1016/j.intimp.2013.03.021 · 2.71 Impact Factor
  • Source
    • "While they may reduce the parasite load of individuals living in endemic areas, they do not mediate sterile protection or total suppression of parasites in the blood (Genton et al., 2002). Recently, an apical merozoite antigen (AMA)-1 based vaccine that induces high antibody titers, and high GIA responses in vitro in human vaccinees (Ellis et al., 2009) was evaluated for its protective effect in a blood challenge. To this end, the vaccinees were immunized and then challenged with blood infected with the 3D7 parasite clone. "
    Malaria Parasites, 03/2012; , ISBN: 978-953-51-0326-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A double blind, randomized and controlled Phase 1 clinical trial was conducted to assess the safety and immunogenicity in malaria-exposed adults of the Plasmodium falciparum blood stage vaccine candidate Apical Membrane Antigen 1-Combination 1 (AMA1-C1)/Alhydrogel with and without the novel adjuvant CPG 7909. Participants were healthy adults 18-45 years old living in the village of Donéguébougou, Mali. A total of 24 participants received 2 doses one month apart of either 80 microg AMA1-C1/Alhydrogel or 80 microg AMA1-C1/Alhydrogel + 564 microg CPG 7909. The study started in October 2007 and completed follow up in May 2008. Both vaccines were well tolerated, with only mild local adverse events and no systemic adverse events judged related to vaccination. The difference in antibody responses were over 2-fold higher in the group receiving CPG 7909 for all time points after second vaccination and the differences are statistically significant (all p<0.05). This is the first use of the novel adjuvant CPG 7909 in a malaria-exposed population.
    Vaccine 10/2009; 27(52):7292-8. DOI:10.1016/j.vaccine.2009.10.087 · 3.49 Impact Factor
Show more